Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status

Charitha Gowda,1,2 Craig W. Newcomb,3 Qing Liu,1 Dena M. Carbonari,24 James D. Lewis,34 Kimberly A. Forde,345 David S. Goldberg,345 K. Rajender Reddy,6,5 Jason A. Roy,34 Amy R. Marks,9 Jennifer L. Schneider,7 Jay R. Kostman,7 Janet P. Tate,8,9 Joseph K. Lim,8,9 Amy C. Justice,8,9 Matthew Bidwell Goetz,26 Douglas A. Corley,6 and Vincent Lo Re III3,4,11

1Division of Pediatric Infectious Diseases, Nationwide Children’s Hospital, Columbus, Ohio; 2Department of Pediatrics, Ohio State University College of Medicine, Columbus; 3Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia; 4Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia; 5Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia; 6Division of Research, Kaiser Permanente Northern California, Oakland; 7Jonathan Lax Treatment Center, Philadelphia FIGHT, Pennsylvania; 8VA Connecticut Healthcare System, West Haven, Connecticut; 9Yale University School of Medicine, New Haven, Connecticut; 10VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, California; and 11Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia

Background. The risk of hepatotoxicity with antiretroviral therapy (ART) remains unknown. We determined the comparative risk of acute liver injury (ALI) for antiretroviral drugs, classes, and regimens, by viral hepatitis status.

Methods. We followed a cohort of 10 083 human immunodeficiency virus (HIV)-infected persons in Kaiser Permanente Northern California (n = 2099) from 2004 to 2010 and the Veterans Aging Cohort Study (n = 7984) from 2004 to 2012. Within the first year of ART, we determined occurrence of (1) liver aminotransferases >200 U/L and (2) severe ALI (coagulopathy with hyperbilirubinemia). We used Cox regression to determine hazard ratios (HRs) with 95% confidence intervals (CIs) of endpoints among initiators of nucleos(t)ide analogue combinations, antiretroviral classes, and ART regimens, all stratified by viral hepatitis status.

Results. Liver aminotransferases >200 U/L developed in 206 (2%) persons and occurred more frequently among HIV/viral hepatitis-coinfected than HIV-monoinfected persons (116.1 vs 20.7 events/1000 person-years; P < .001). No evidence of differential risk was found between initiators of abacavir/lamivudine versus tenofovir/emtricitabine among coinfected (HR, 0.68; 95% CI, .29–1.57) or HIV-monoinfected (HR, 1.19; 95% CI, .47–2.97) groups. Coinfected patients had a higher risk of aminotransferases >200 U/L after initiation with a protease inhibitor than nonnucleoside reverse-transcriptase inhibitor (HR, 2.01; 95% CI, 1.36–2.96). Severe ALI (30 events; 0.3%) occurred more frequently in coinfect persons (15.9 vs 3.1 events/1000 person-years; P < .001) but was too uncommon to evaluate in adjusted analyses.

Conclusions. Within the year after ART initiation, aminotransferase elevations were infrequently observed and rarely led to severe ALI. Protease inhibitor use was associated with a higher risk of aminotransferase elevations among viral hepatitis-coinfected patients.

Keywords. antiretroviral; drug-induced liver injury; hepatotoxicity; HIV.

The introduction of new antiretroviral drugs over the last decade has transformed the treatment of human immunodeficiency virus (HIV) infection [1, 2]. Current antiretrovirals, including the integrase strand transfer inhibitors (INSTIs) and newer protease inhibitors (PIs) such as atazanavir and darunavir, are highly efficacious [3–5]. However, antiretrovirals have been associated with acute liver injury (ALI) [6–8], manifested by liver aminotransferase elevations or, in more serious cases, hepatic dysfunction (characterized by coagulopathy and hyperbilirubinemia [9]) and acute liver failure (ALF).

Prior studies of HIV-infected patients initiating antiretroviral therapy (ART) reported that the incidence of ALI ranged from 2% to 18%, with higher risk associated with increasing age, viral hepatitis coinfection, and pre-existing liver aminotransferase elevations [6, 10–12]. However, these studies focused on risks associated with individual antiretrovirals used in the early ART era and did not stratify results by viral hepatitis status [6, 7, 11–15]. Analyses that evaluate antiretroviral-associated hepatotoxicity in clinical practice settings are important to ensure the safety of these medications among HIV-infected individuals, particularly those with viral hepatitis coinfection.

We determined the absolute and comparative risks of ALI associated with nucleos(t)ide analogue combinations, antiretroviral classes, and commonly used ART regimens by examining incident development of liver aminotransferase elevations...
and hepatic dysfunction within the first year after ART initiation among those with and without viral hepatitis coinfection. We also determined factors associated with ALI. To accomplish these objectives, we combined data from 2 integrated health systems, Kaiser Permanente Northern California (KPNC) and the Veterans Health Administration, to create a large, nationally representative cohort of HIV-infected persons initiating ART in whom to evaluate ALI events.

METHODS

Study Design and Data Sources
We conducted a retrospective cohort study of HIV-infected persons who initiated ART within KPNC and the Veterans Aging Cohort Study (VACS), both of which utilize electronic medical records, permitting determination of dispensed antiretrovirals and laboratory-based definitions of ALI [16, 17].

The KPNC is an integrated healthcare organization that provides inpatient and outpatient services to Northern California residents [16]. The KPNC HIV Registry identifies members with a positive HIV antibody test, detectable HIV ribonucleic acid (RNA), antiretroviral prescription, or HIV/acquired immune deficiency syndrome (AIDS)-related diagnosis. Medical chart review is performed to confirm diagnoses. Data collected from KPNC include demographics, inpatient/outpatient International Classification of Diseases, Ninth Revision (ICD-9) diagnoses, procedures, laboratory results, and dispensed medications. Deaths are identified within the KPNC mortality database.

The VACS consists of electronic medical record data from HIV-infected patients receiving care at Veterans Affairs (VA) medical facilities across the United States. Data include demographics, inpatient/outpatient ICD-9 diagnoses, procedures, laboratory results, and pharmacy data. Deaths are identified from the VA Vital Status file [18].

This study was approved by the Institutional Review Boards of the University of Pennsylvania, KPNC, and Corporal Michael J. Crescenz Philadelphia VA Medical Center.

Study Patients
Patients were eligible if they were (1) HIV antibody- and/or RNA-positive, (2) ≥18 years old, (3) dispensed ART (defined as use of ≥3 antiretrovirals from 2 different classes [19]) in an outpatient setting within KPNC between January 1, 2004 and December 31, 2010 or within VACS between January 1, 2004 and September 30, 2012, (4) without any antiretroviral fills in the prior 12 months, and (5) continuously enrolled in KPNC or VACS for ≥1 year. Patients were excluded if they had baseline evidence of any ALI outcome (defined below) or received warfarin (preventing identification of coagulopathy due to severe ALI).

The index date was the date the ART regimen was initially dispensed. The 12 months before this date represented the baseline period. Follow-up continued until (1) study endpoint (defined below), (2) death, (3) warfarin dispensation, (4) ART discontinuation (ie, no further antiretroviral medication fills within 30 days after the last prescription's days' supply) or change in ART regimen, (5) 1 year after index date, or (6) last contact before December 31, 2010 in KPNC or December 31, 2012 in VACS, whichever occurred first. For patients who discontinued ART, follow-up was censored on the end of the days' supply of the first antiretroviral discontinued.

Main Study Outcomes
We examined 3 categories of outcomes within 12 months after ART initiation (to increase the likelihood that ALI events were antiretroviral-associated). First, we determined development of liver aminotransferase elevations, defined as an inpatient or outpatient alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >200 U/L (~5 times the upper limit of normal [ULN] of the assays used), a threshold that represents clinically important hepatic injury [20] and ~10 times what has been considered normal liver aminotransferase levels for males (30 U/L) and females (19 U/L) [21]. As a secondary endpoint, we determined incident grade 3 or 4 aminotransferase elevations determined by the toxicity grade scale used by the AIDS Clinical Trials Group [22], an outcome evaluated in prior studies of antiretroviral-induced ALI [10, 11, 14]. As was done in those studies [10, 11, 14], patients with pre-ART aminotransferases below ULN (ALT, 36 IU/L; AST, 40 IU/L) were classified, based on changes relative to ULN, as having incident grade 3 (>3.5 times ULN) or grade 4 (>5 times ULN) elevations. Patients with pre-ART aminotransferases above ULN were classified, based on changes relative to the baseline value, as having incident grade 3 (>3.5 times baseline) or grade 4 (>5 times baseline) elevations. Patients who did not have ALT/AST measured before ART initiation were excluded from analyses of grade 3/4 aminotransferase elevations.

Second, we evaluated severe ALI, defined by development of both international normalized ratio (INR) ≥1.5 and total bilirubin >2 times ULN in an inpatient or outpatient setting within 30 days of each other [23]. This definition indicates severe hepatic dysfunction and has been used by the US Food and Drug Administration's Sentinel Initiative to assess serious drug-induced hepatotoxicity in the postmarketing setting [23].

Finally, we evaluated incident ALF among ART initiators without viral hepatitis, because pre-existing liver disease precludes an ALF diagnosis [24]. Acute liver failure was defined by coagulopathy (INR ≥1.5) plus either hepatic encephalopathy or liver transplantation [24].

Data Collection
Baseline clinical data included the following: age, sex, race, obesity (body mass index >30 kg/m²), alcohol dependence/abuse, cancer (excluding nonmelanoma skin cancers), diabetes mellitus, heart failure, and ART regimen. Alcohol dependence/abuse...
and heart failure [26] were defined by validated ICD-9 diagnoses. Within KPNC, diabetes and cancer were determined by registries. Within VACS, diabetes was defined by random glucose ≥200 mg/dL, ICD-9 diagnosis, and/or anti diabetic medication use [27], and cancer was determined by ICD-9 diagnosis. Baseline laboratory data included ALT, AST, INR, total bilirubin, platelets, pre-ART CD4 count and HIV RNA, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and HCV RNA. To minimize misclassification of viral hepatitis status, patients who ever had a positive HBsAg, HCV antibody, or HCV RNA during the study period were classified as viral hepatitis-coinfected.

Data collected during follow-up included outpatient and inpatient ALT, AST, INR, and total bilirubin. We determined ALF events among patients without viral hepatitis using a method we previously described [9, 28]. Patients were screened for potential ALF if, during the year after ART initiation, they had the following: (1) a hospital ICD-9 diagnosis suggestive of ALF (Supplementary Appendix 1) and (2) both an inpatient INR ≥1.5 and peak total bilirubin ≥5.0 mg/dL. Hospital records of these patients were independently reviewed by 2 hepatologists (K.A.F. and D.S.G.). Acute liver failure was confirmed if a patient was hospitalized and had (1) no chronic liver disease, (2) coagulopathy (INR ≥1.5), and (3) either hepatic encephalopathy or liver transplantation [24]. Disagreements in ALF classification were arbitrated by a third hepatologist (K.R.R.).

Statistical Analysis
One-year cumulative risk and incidence rates (events/1000 person-years) of outcomes with 95% confidence intervals (CIs) of outcomes were calculated for individual antiretrovirals, nucleos(t)ide reverse transcriptase inhibitor (NRTI) combinations, antiretroviral classes, and commonly prescribed ART regimens. Results were stratified by viral hepatitis status.

Cox regression was used to estimate adjusted hazard ratios (HRs) of endpoints among initiators of NRTI combinations, antiretroviral classes, and ART regimens [29]. We determined whether HRs of outcomes differed by viral hepatitis status through use of statistical tests of interaction within Cox models. Severe ALI and ALF were too rare to evaluate with multivariable Cox regression. Thus, multivariable analyses focused on liver aminotransferase elevations. Three models were developed, stratified by viral hepatitis status, to assess the risk of this endpoint among initiators of the following: (1) NRTI combinations; (2) PI, INSTI, and non-NRTI classes; and (3) common ART regimens. For each analysis, the most frequently prescribed NRTI combination (tenofovir plus either emtricitabine or lamivudine), antiretroviral class (non-NRTI), or ART regimen (efavirenz plus tenofovir/emtricitabine) was the reference. Analyses were adjusted for variables that were significantly (P < .05) associated with incident outcomes in univariable analyses. Proportionality of hazards was assessed by Schoenfeld residuals [30].

Figure 1. Selection of patients into the study from Kaiser Permanente Northern California and the Veterans Aging Cohort Study. Index Date is the earliest qualifying date the antiretroviral therapy was dispensed in an outpatient setting on or after January 1, 2004. Severe acute liver injury is defined as total bilirubin >2 times the upper limit of normal and an international normalized ratio (INR) ≥1.5 in an inpatient or outpatient setting. Acute liver injury is defined as (1) inpatient or outpatient alanine aminotransferase or aspartate aminotransferase >200 U/L, (2) a total bilirubin >2 times the upper limit of normal and an INR ≥1.5 in an inpatient or outpatient setting; or (3) inpatient INR ≥1.5 and either hepatic encephalopathy or liver transplantation in the absence of chronic liver disease. KPNC, Kaiser Permanente Northern California; VACS, Veterans Aging Cohort Study.
Cox regression was also used to identify risk factors for aminotransferases >200 U/L in multivariable analysis and severe ALI in univariable analyses (given the rarity of these events). Age, sex, race, obesity, viral hepatitis, alcohol dependence/abuse, diabetes, cancer, heart failure, pre-ART CD4 count, pre-ART HIV RNA level, and baseline ALT were evaluated as risk factors.

To avoid bias from excluding subjects with missing data for models evaluating aminotransferases >200 U/L, we implemented multiple imputation using chained equations [31]. Ten imputed datasets were created using all variables. Imputed variables included baseline ALT, obesity, and pre-ART CD4 count and HIV RNA. Results across the 10 datasets were combined to arrive at CIs that accounted for within- and across-dataset variabilities [32]. Data were analyzed using SAS 9.4 (SAS Institute Inc., Cary, NC).

**RESULTS**

**Patient Characteristics**

Among 24,868 patients dispensed ART within KPNC (n = 8,789) and VACS (n = 16,079), 10,083 persons (2099 in KPNC; 7984 in VACS) met eligibility and were followed for 5461 person-years (Figure 1). The VACS patients were older, more commonly male or African American, less commonly Hispanic, and had a higher prevalence of viral hepatitis, alcohol dependence/abuse, and diabetes.

### Table 1. Baseline Characteristics of HIV-Infected Patients Who Were Dispensed Antiretroviral Therapy in an Outpatient Setting Within Kaiser Permanente Northern California (2004–2010) and the Veterans Aging Cohort Study (2004–2012)

| Characteristic                          | Overall (n = 10,083) | Veterans Aging Cohort Study (n = 7,984) | Kaiser Permanente Northern California (n = 2,099) |
|----------------------------------------|----------------------|----------------------------------------|-----------------------------------------------|
| Median follow-up (months, IQR)         | 5.29 (2.14–12.0)     | 4.75 (1.94–12.0)                       | 9.53 (2.99–12.0)                              |
| Age (n, %)                              | 48.0 (40.0–53.0)     | 49.0 (42.0–56.0)                       | 43.0 (37.0–50.0)                              |
| 18–50 years                             | 5686 (56.4%)         | 4151 (52.0%)                           | 1535 (70.3%)                                  |
| 50–59 years                             | 4397 (43.6%)         | 3833 (48.0%)                           | 564 (29.6%)                                   |
| Female sex (n, %)                       | 511 (5.1%)           | 248 (3.1%)                             | 263 (12.5%)                                   |
| Race (n, %)                             |                      |                                        |                                               |
| White                                  | 3973 (39.4%)         | 2942 (36.8%)                           | 1031 (49.1%)                                  |
| Black or African American              | 4972 (49.3%)         | 4573 (57.3%)                           | 399 (19.0%)                                   |
| Asian/Native Hawaiian/Other Pacific Islander | 200 (2.0%)         | 81 (1.0%)                              | 119 (5.7%)                                    |
| American Indian/Alaska Native          | 53 (0.5%)            | 37 (0.5%)                              | 16 (0.8%)                                     |
| Unknown/Multiracial                    | 885 (8.8%)           | 351 (4.4%)                             | 534 (25.4%)                                   |
| Hispanic (n, %)                         | 939 (9.3%)           | 546 (6.8%)                             | 393 (18.7%)                                   |
| Unknown                                | 467 (4.6%)           | 0 (0%)                                 | 467 (22.2%)                                   |
| Body mass index $\geq$ 30 kg/m$^2$ (n, %) | 1659 (17.3%)       | 1275 (16.2%)                           | 384 (22.1%)                                   |
| Unknown                                | 473 (4.7%)           | 108 (1.4%)                             | 365 (17.4%)                                   |
| Viral hepatitis coinfection (n, %)      |                      |                                        |                                               |
| Hepatitis B*                            | 326 (3.2%)           | 241 (3.0%)                             | 85 (4.0%)                                     |
| Hepatitis C*                            | 1825 (18.1%)         | 1636 (20.5%)                           | 189 (9.0%)                                    |
| History of alcohol dependence/abuse    | 2368 (23.5%)         | 1980 (24.8%)                           | 388 (18.5%)                                   |
| Diabetes mellitus (n, %)                | 929 (9.2%)           | 805 (10.1%)                            | 124 (6.5%)                                    |
| Cancer (n, %)                           | 643 (6.4%)           | 509 (6.4%)                             | 134 (6.4%)                                    |
| Heart failure (n, %)                    | 189 (1.9%)           | 169 (2.1%)                             | 20 (1.0%)                                     |
| Median HIV viral load ($\log_{10}$ copies/mL, IQR) | 4.7 (4.2–5.2)       | 4.8 (4.2–5.2)                          | 4.6 (4.1–5.1)                                 |
| Missing (n, %)                          | 333 (3.3%)           | 84 (1.1%)                              | 249 (11.9%)                                   |
| CD4 cell count (n, %)                   |                      |                                        |                                               |
| Median (cells/mm$^3$, IQR)              | 244 (119–354)        | 237 (110–350)                          | 265 (160–368)                                 |
| <200 cells/mm$^3$                       | 3971 (40.0%)         | 3307 (41.1%)                           | 664 (33.0%)                                   |
| 200–500 cells/mm$^3$                    | 4999 (50.4%)         | 3884 (49.1%)                           | 1116 (55.4%)                                  |
| $\geq$500 cells/mm$^3$                  | 950 (9.6%)           | 717 (9.1%)                             | 233 (11.6%)                                   |
| Missing                                 | 163 (1.6%)           | 76 (1.0%)                              | 87 (4.1%)                                     |
| Median ALT (IU/mL, IQR)                 | 29 (20–43)           | 29 (20–44)                             | 29 (20–41)                                    |
| Missing (n, %)                          | 744 (7.4%)           | 353 (4.4%)                             | 391 (18.6%)                                   |
| Calendar year of ART initiation, n (%)  |                      |                                        |                                               |
| 2004–2006                               | 3967 (39.3%)         | 3139 (39.3%)                           | 828 (39.4%)                                   |
| 2007–2009                               | 3511 (34.8%)         | 2549 (31.9%)                           | 962 (45.8%)                                   |
| 2010–2012                               | 2605 (25.8%)         | 2296 (28.8%)                           | 309 (14.7%)                                   |

Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid.

*Hepatitis B virus infection defined by ever-positive hepatitis B surface antigen.

*Hepatitis C virus infection defined by ever-positive hepatitis C virus antibody or hepatitis C virus RNA.
than KPNC members (Table 1). Median pre-ART CD4, pre-ART HIV RNA, and baseline ALT were similar between the groups.

**Risk of Liver Aminotransferase Elevations**

During the study period, 206 patients (n = 10,083; 2.0%) developed aminotransferases >200 U/L and 178 (n = 9,542; 1.9%) developed grade 3/4 aminotransferase elevations. Viral hepatitis-coinfected patients had higher rates of both aminotransferases >200 U/L (Table 2; Supplementary Appendix 2) and grade 3/4 elevations (Supplementary Appendix 3) than KPNC members (Table 1). Relative hazards of this outcome associated with different NRTI combinations did not differ by viral hepatitis status (test of interaction, P > .20). Among HIV-monoinfected and viral hepatitis-coinfected persons, initiators of abacavir/lamivudine and zidovudine/lamivudine did not have a greater risk of aminotransferases >200 U/L versus tenofovir/emtricitabine (or lamivudine) initiators, after adjustment for baseline ALT, year of ART initiation, and data source (Figure 2, Model A).

**Risk With Nucleos(t)ide Reverse-Transcriptase Inhibitor Combinations**

Absolute risks and rates of different aminotransferases >200 U/L for initiators of different NRTI combinations were similar among HIV-monoinfected and HIV/viral hepatitis-coinfected patients (Table 2).

### Table 2. Cumulative Incidences and Incidence Rates of Liver Aminotransferases >200 U/L Among Initiators of Antiretroviral Drugs and Regimens Within Kaiser Permanente Northern California (2004–2010) and the Veterans Aging Cohort Study (2004–2012), Stratified by the Presence of Viral Hepatitis Coinfection

| Regimen/Drug | Without Viral Hepatitis Coinfection | With Viral Hepatitis Coinfection |
|--------------|-------------------------------------|---------------------------------|
|               | No. Exposed | No. Events | Person-Time | Cumulative Incidence at 1 Year/100 Persons (95% CI) | Incidence Rate, Events/1000 Person-Years (95% CI) | No. Exposed | No. Events | Person-Time | Cumulative Incidence at 1 Year/100 Persons (95% CI) | Incidence Rate, Events/1000 Person-Years (95% CI) |
| Overall       | 7970        | 93         | 4488        | 1.7 (1.4–2.2) | 20.7 (16.7–25.4) | 2113 | 113 | 973 | 9.0 (7.4–11.0) | 116.1 (95.7–139.6) |
| NRTI Components |          |            |            |            |                |            |        |          |            |          |
| TDF/FTC or TDF/3TC | 5762 | 66 | 3484 | 1.6 (1.3–2.1) | 19.1 (14.7–24.2) | 1343 | 73 | 674 | 8.3 (6.6–10.6) | 108.3 (84.9–136.2) |
| ABC/3TC       | 392        | 5          | 211         | 2.2 (0.9–5.4) | 23.6 (7.7–55.2) | 162 | 6   | 71  | 5.9 (2.5–13.5) | 84.9 (31.1–184.7) |
| 3TC/ZDV       | 1032       | 9          | 481         | 1.3 (0.6–2.7) | 18.7 (8.6–35.5) | 344 | 20  | 129 | 12.9 (7.7–21.0) | 156.0 (94.7–239.3) |
| Other\(^a\)   | 784        | 13         | 332         | 2.8 (1.6–5.1) | 39.2 (20.9–67.0) | 264 | 14  | 100 | 13.3 (7.2–23.9) | 140.7 (76.9–236.0) |
| Antiretroviral Class |          |            |            |            |                |            |        |          |            |          |
| Non-NRTI      | 4937       | 59         | 2948        | 1.7 (1.3–2.3) | 20.0 (15.2–25.8) | 1148 | 47  | 568 | 6.9 (5.1–9.3) | 82.7 (60.7–109.9) |
| PI            | 2520       | 25         | 1299        | 1.5 (1.0–2.3) | 19.2 (12.5–28.4) | 833  | 59  | 356 | 12.0 (9.1–15.6) | 165.8 (126.2–213.9) |
| INSTI         | 195        | 5          | 112         | 3.4 (1.3–8.6) | 44.7 (14.5–104.4) | 33   | 1   | 14  | 8.3 (1.2–46.1) | 72.8 (18.4–405.8) |
| Other\(^b\)   | 318        | 4          | 129         | 2.3 (0.8–7.1) | 31.1 (8.5–79.6) | 99   | 6   | 35  | 12.2 (4.5–30.3) | 170.5 (62.6–371.1) |

Commonly Used Regimens

| Regimen/Drug | Without Viral Hepatitis Coinfection | With Viral Hepatitis Coinfection |
|--------------|-------------------------------------|---------------------------------|
| EFV/TDF/FTC  | 3697 | 42 | 2320 | 1.6 (1.2–2.3) | 18.1 (13.0–24.6) |
| ATV/r + TDF/FTC | 854 | 11 | 511 | 1.8 (0.9–3.3) | 21.5 (10.7–39.8) |
| EFV + 3TC/ZDV | 556 | 2 | 270 | 0.8 (0.2–3.7) | 7.4 (0.9–26.7) |
| LPV/r + TDF/FTC | 276 | 3 | 131 | 1.2 (0.4–3.5) | 22.8 (4.7–66.7) |
| LPV/r + 3TC/ZDV | 221 | 1 | 95 | 1.0 (0.1–6.6) | 10.5 (0.3–58.7) |
| DRV/r + TDF/FTC | 224 | 1 | 119 | 0.5 (0.1–3.2) | 8.4 (0.2–46.6) |
| ATV/r + ABC/3TC | 150 | 2 | 80 | 2.3 (0.6–9.4) | 24.9 (3.0–89.8) |
| RAL + TDF/FTC  | 174 | 5 | 102 | 3.7 (1.4–9.3) | 49.1 (16.0–114.6) |
| EFV + TDF/FTC  | 126 | 1 | 70 | 1.9 (0.3–12.6) | 14.3 (0.4–79.6) |
| EFV + ABC/3TC  | 318 | 4 | 129 | 2.3 (0.8–7.1) | 31.1 (8.5–79.6) |

Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; CI, confidence interval; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; LPV, lopinavir; NRTI, nucleos(t)ide reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; r, ritonavir; RAL, raltegravir; TDF, tenofovir; ZDV, zidovudine.

\(^a\)“Other” category includes regimens with <2 NRTIs or alternative NRTI combinations than those listed above.

\(^b\)“Other” includes regimens unable to be classified in the prior categories, such as those with none or >1 antiretroviral class.
associated with antiretroviral classes differed by viral hepatitis status (test of interaction, \( P = .05 \)). Among HIV-monoinfected persons, adjusted HRs did not differ between antiretroviral classes. However, among viral hepatitis-coinfected persons, those who initiated a PI-based regimen had a higher risk of aminotransferases >200 U/L than those initiating non-NRTI-based regimens (HR, 2.01; 95% CI, 1.36–2.96) (Figure 2, Model B). Among coinfected patients, initiation of INSTI-based ART was not associated with a higher risk of aminotransferases >200 U/L versus non-NRTI-based ART (HR, 0.98; 95% CI, 0.13–7.22).

**Risk With Antiretroviral Therapy Regimens**

Between 2004 and 2012, the most commonly prescribed ART regimens were as follows: efavirenz plus tenofovir/emtricitabine (44.2%) or zidovudine/lamivudine (7.4%); atazanavir/ritonavir plus tenofovir/emtricitabine (11.0%) or abacavir/lamivudine (2.0%); lopinavir/ritonavir plus tenofovir/emtricitabine (3.6%) or zidovudine/lamivudine (2.9%); darunavir/ritonavir plus tenofovir/emtricitabine (2.7%); and raltegravir plus tenofovir/ emtricitabine (2.0%). Table 2 presents the absolute risks and rates of aminotransferases >200 U/L for these regimens, stratified by viral hepatitis status. Hazard ratios for different ART regimens did not differ by viral hepatitis status (test of interaction, \( P > .20 \)). Among HIV-monoinfected persons, there were no significant differences in the risk of aminotransferases >200 U/L associated with initiation of these regimens compared with efavirenz plus tenofovir/emtricitabine, after adjustment for baseline ALT, year of ART initiation, and data source (Figure 2, Model C). Among viral hepatitis–coinfected individuals, there was a higher risk of aminotransferases >200 U/L associated with initiation of darunavir/ritonavir plus tenofovir/emtricitabine (HR, 4.25; 95% CI, 1.45–12.51), atazanavir/ritonavir plus tenofovir/emtricitabine (HR, 2.02; 95% CI, 1.11–3.67), and lopinavir/ritonavir plus zidovudine/lamivudine (HR, 2.58; 95% CI, 1.02–6.57) compared with efavirenz plus tenofovir/emtricitabine.

**Severe Acute Liver Injury and Acute Liver Failure**

Thirty (0.3%) patients developed severe ALI. Viral hepatitis–coinfected individuals had a higher rate of severe ALI than those without viral hepatitis (Table 3; Supplementary Appendix 4). Severe ALI events were too rare to allow evaluation within multivariable models. Among the 7970 patients without viral hepatitis, none developed ALF within the first year of ART initiation.

**Risk Factors for Acute Liver Injury Events**

Factors associated with development of aminotransferases >200 U/L included viral hepatitis and baseline ALT >40 U/L (Table 4). Viral hepatitis, heart failure, age >50 years, and higher baseline HIV RNA were associated with severe ALI (Table 4).
Overall 7970 14 4515 0.2 (0.1–0.4) 3.1 (1.7–5.2) 2113 16 1005 1 .2 (0.7–2.1) 15.9 (9.1–25.9)

NRTI Components; or ART regimens. Taken together, these results highlight among different NRTI combinations; PI, INSTI, or non-NRTI patients, no differences in the risk of this outcome were found virusen plus tenofovir/emtricitabine. Among HIV-monoinfected plus zidovudine/lamivudine compared with those initiating efavirenz plus tenofovir/emtricitabine, and lopinavir/ritonavir plus zidovudine/lamivudine compared with those initiating efavirenz plus tenofovir/emtricitabine. Among HIV-monoinfected patients, no differences in the risk of this outcome were found among different NRTI combinations; PI, INSTI, or non-NRTI classes; or ART regimens. Taken together, these results highlight the rarity of antiretroviral-associated ALI and provide evidence for the hepatic safety of these regimens among HIV-infected patients with and without viral hepatitis.

As in prior studies of antiretroviral-associated hepatotoxicity in the early ART era [6, 11, 13, 33], viral hepatitis coinfection was associated with higher rates of ALI. Our observation that use of PI-based ART increased the risk of aminotransferase elevations compared with non-NRTI-based ART among viral hepatitis-coinfected patients is consistent with a study of 155 HIV/HCV-coinfected patients from 5 sites across Italy. Protease inhibitor-based ART initiators had a higher incidence of aminotransferase elevations >5 times ULN than non-NRTI-based ART initiators [15]. A study of 568 HIV-infected patients initiating ART at Johns Hopkins Hospital HIV Clinic found that concurrent PI and non-NRTI use was associated with increased risk of hepatotoxicity among viral hepatitis-coinfected patients [14]. Finally, an analysis of 1982 HIV-infected patients initiating ART at Hospital Carlos III in Spain found that aminotransferase elevations >5 times baseline occurred more commonly in HIV/HCV-coinfected

| Regimen/Drug | Without Viral Hepatitis Coinfection | With Viral Hepatitis Coinfection |
|--------------|-----------------------------------|----------------------------------|
|              | No. Exposed | No. Events | Person-Time | Cumulative Incidence at 1 Year/100 Persons (95% CI) | Incidence Rate, Events/1000 Person-Years (95% CI) | No. Exposed | No. Events | Person-Time | Cumulative Incidence at 1 Year/100 Persons (95% CI) | Incidence Rate, Events/1000 Person-Years (95% CI) |
| TDF/FTC or TDF/3TC | 5762 12 | 3486 | 0.3 (0.1–0.5) | 3.4 (1.8–6.0) | 1343 | 9 | 695 | 1.1 (0.5–2.2) | 12.9 (5.9–24.8) |
| ABC/3TC | 392 0 | 212 | 0.0 (0.0–0.0) | 0.0 (0.0–14.1) | 162 2 | 72 | 1.4 (0.4–5.8) | 27.8 (3.4–100.5) |
| 3TC/ZDV | 1032 0 | 482 | 0.0 (0.0–0.0) | 0.0 (0.0–6.2) | 344 3 | 135 | 1.7 (0.5–6.0) | 22.2 (4.6–65.0) |
| Othera | 5762 2 | 334 | 0.3 (0.1–1.0) | 6.0 (0.7–21.6) | 264 2 | 103 | 0.8 (0.2–3.1) | 19.4 (2.4–70.2) |
| Non-NRTI | 4937 4 | 2968 | 0.1 (0.0–0.3) | 1.3 (0.4–3.5) | 1148 10 | 581 | 1.5 (0.7–3.0) | 17.2 (8.3–31.7) |
| PI | 2520 10 | 1303 | 0.5 (0.3–0.9) | 7.7 (3.7–14.1) | 833 5 | 373 | 0.7 (0.3–1.8) | 13.4 (4.3–31.3) |
| INSTI | 195 0 | 114 | 0.0 (0.0–0.0) | 0.0 (0.0–26.3) | 33 0 | 14 | 0.0 (0.0–0.0) | 0.0 (0.0–210.8) |
| Otherb | 318 0 | 130 | 0.0 (0.0–0.0) | 0.0 (0.0–23.1) | 99 1 | 37 | 1.1 (0.2–7.4) | 27.1 (7.0–151.1) |

**DISCUSSION**

In this study of HIV-infected patients initiating ART within 2 of the largest integrated healthcare systems in the United States, we found low absolute risks and rates of ALI within the first year of ART. Although liver aminotransferases >200 U/L and grade 3/4 elevations occurred in 2% of the cohort, severe ALI, manifested by coagulopathy and hyperbilirubinemia, developed in <1%, and no ALF events were identified among patients without viral hepatitis coinfection. Rates of ALI were higher for viral hepatitis-coinfected patients. Among these individuals, initiation of PI-based ART was associated with a higher risk of aminotransferases >200 U/L compared with initiation of non-NRTI-based ART. The risk was significantly higher for coinfected initiators of darunavir/ritonavir plus tenofovir/emtricitabine, atazanavir/ritonavir plus tenofovir/emtricitabine, and lopinavir/ritonavir plus zidovudine/lamivudine compared with those initiating efavirenz plus tenofovir/emtricitabine. Among HIV-monoinfected patients, no differences in the risk of this outcome were found among different NRTI combinations; PI, INSTI, or non-NRTI classes; or ART regimens. Taken together, these results highlight the rarity of antiretroviral-associated ALI and provide evidence for the hepatic safety of these regimens among HIV-infected patients with and without viral hepatitis.
patients treated with PIs, particularly darunavir and atazanavir, than with raltegravir or etravirine [34]. The reasons why PIs might increase the risk of aminotransferase elevations among viral hepatitis-coinfected patients remain unclear. Protease inhibitors are associated with up-regulation of proinflammatory cytokines and alterations in lipid metabolism that could promote liver injury [35, 36], and these effects might be exacerbated by viral hepatitis. Viral hepatitis-mediated liver disease may also impair drug metabolism and clearance, further contributing to drug-related hepatotoxicity [37]. More importantly, although the risk of aminotransferase elevations after PI-based ART initiation was increased in coinfected patients, there were very few severe ALI events among these individuals. Thus, providers should not be reluctant to initiate PIs in viral hepatitis-coinfected patients.

This study identified several factors, including viral hepatitis coinfection, heart failure, older age, and higher pre-ART HIV RNA levels, that might increase ALI risk. Viral hepatitis and heart failure can each contribute to hepatic fibrosis, which could impair the liver’s ability to tolerate acute insults from drug-induced ALI [37, 38]. Older HIV-infected patients are more likely to have other comorbidities and polypharmacy [39], which could increase exposure to hepatotoxic medications or drug-drug interactions. Finally, patients with high pre-ART HIV RNA levels might have more vigorous immune reconstitution after ART initiation. Patients with these characteristics might benefit from closer monitoring of liver aminotransferases after ART initiation.

Our study has several potential limitations. First, severe ALI and ALF events were rare, and analyses of these outcomes could
not adjust for potential confounders. Moreover, absolute risks and rates for some antiretrovirals, such as integrase inhibitors, were based on small sample sizes. Second, the ALI outcomes in this study could have been due to other conditions, such as patient comorbidities or concurrent medications for which we did not collect complete data. To minimize this possibility, we focused on ALI events that developed within the first year of ART initiation. Third, because pre-existing liver disease precludes a diagnosis of ALF [24], we did not determine this outcome among viral hepatitis-coinfected patients. For patients with pre-existing liver disease, definitions for the acute deterioration of liver function due to drug-induced or other etiologies (“acute-on-chronic liver failure”) have only recently been proposed [40]. Validated methods to ascertain these events within electronic health data have not been developed, preventing us from ascertaining them among hepatitis-coinfected patients.

CONCLUSIONS

In summary, severe ALI events were rare among HIV-infected persons initiating ART. Patients with viral hepatitis had higher rates of aminotransferase elevations and hepatic dysfunction than those with HIV alone. Among viral hepatitis-coinfected patients, initiation of PI-based ART, particularly with darunavir/ritonavir, atazanavir/ritonavir, and lopinavir/ritonavir, was associated with a higher risk of aminotransferase elevations than with non-NRTI-based ART, but acute hepatic dysfunction was uncommon among these individuals.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

Author contributions. All authors had access to the data and a role in writing this manuscript. C. G. and V. L. R. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of data analyses. C. G., J. R. K., D. A. C., and V. L. R. contributed to the study concept and design. D. M. C., K. A. F., D. S. G., K. R. R., A. R. M., J. L. S., J. P. T., A. C. J., D. A. C., and V. L. R. acquired the data. C. G., C. W. N., Q. L., D. M. C., J. A. R., A. R. M., J. L. S., and D. A. C. analyzed and interpreted the data. C. G., C. W. N., D. M. C., J. A. R., J. R. K., D. A. C., and V. L. R. drafted the manuscript. C. G., C. W. N., Q. L., D. M. C., J. A. R., A. R. M., J. L. S., J. P. T., J. K. L., A. C. J., M. B. G., D. A. C., and V. L. R. critically reviewed the manuscript. V. L. R. obtained funding. D. M. C., J. P. T., J. L. S., A. C. J., D. A. C., and V. L. R. supervised the study.

Disclaimer. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.

Financial support. This study was funded by research grants from the Agency for Healthcare Research and Quality (Grant R01 HS018372; to V. L. R.), the National Institutes of Health (Grants F32 AI120363 [to C. G.] and K24 DK078228 [to J. D. L.]), and the National Institute on Alcohol Abuse and Alcoholism (Grants U01 AA13566, U24 AA20794, and U01 AA20790; to A. C. J.).

Potential conflicts of interest. V. L. R., D. M. C., and J. A. R. have received research grant support (to the University of Pennsylvania) from Abbvie, J. D. L. has received research grant support (to the University of Pennsylvania) from Bayer, Nestle Health Science, and Takeda and has served as a consultant to AstraZeneca, Amgen, MedImmune, Merck, Nestle Health Science, Gilead, Pfizer, Rebiotix, and Takeda. D. S. G. has received research grant support (to the University of Pennsylvania) from Bayer HealthCare, Intercept Pharmaceuticals, and Merck. K. R. R. has received research grant support (to the University of Pennsylvania) from Abbvie, Bristol-Myers Squibb, Gilead, Janssen, and Merck and has served as an advisor to Abbvie, Bristol-Myers Squibb, Gilead, Janssen, and Merck. D. A. C. has received research grant support (to Kaiser Permanente) from Pfizer. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293–9.
2. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009; 4:194–9.
3. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395–402.
4. Lennox JL, DeJesus E, Lazarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:896–906.
5. Squires K, Lazarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV, J Acquir Immune Defic Syndr 2004; 36:1011–9.
6. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1–13.
7. Jones M, Núñez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012; 32:167–76.
8. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 2015; 148:1340–52.e7.
9. Lo Re V 3rd, Carbonari DM, Forde KA, et al. Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 2015; 24:676–83.
10. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277–84.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74–80.
12. Bell MJ, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29:337–47.
13. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895–902.
14. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182–9.
15. Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis 2005; 5:58.
16. Friedman G, Habel L, Boles M, McFarland B. Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. West Sussex: John Wiley & Sons, Ltd, 2000: pp 263–83.
17. Fulth SL, Skanderson M, Mole LA, et al. Development and verification of a “virtual” cohort using the National VA Health Information System. Med Care 2006; 44(8 Suppl 2):S25–30.
18. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol 1995; 141:242–50.
19. Thompson MA, Aberg JA, Hoy JE, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387–402.
20. Athal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89:806–15.
21. Prati D, Taisoli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137:1–10.
22. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
23. Lo Re V 3rd, Haynes K, Goldberg D, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US food and drug administration’s mini-sentinel distributed database. Pharmacoepidemiol Drug Saf 2013; 22:861–72.
24. Polson J, Let WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41:1179–97.
25. Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care 2006; 44(8 Suppl 2):S52–60.
26. Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1):129–40.
27. Butt AA, Fultz SL, Kwoh CK, et al. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004; 40:115–9.
28. Goldberg DS, Forde KA, Carbonari DM, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 2015; 148:1353–61.e3.
29. Collett D. Modelling Survival Data in Medical Research. Second ed. Boca Raton, FL: Chapman and Hall/CRC CRC Press LLC; 2003.
30. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. New York, NY: John Wiley & Sons, Inc., 1999.
31. Newgard CD, Lewis RJ. Missing data: how to best account for what is not known. JAMA 2015; 314:940–1.
32. Freedman VA, Wolf DA. A case study on the use of multiple imputation. Demography 1995; 32:459–70.
33. Núñez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426–31.
34. Vispo E, Fernández-Montero JV, Labarga P, et al. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS 2013; 27:1187–8.
35. Wu X, Li Y, Peng K, Zhou H. HIV protease inhibitors in gut barrier dysfunction and liver injury. Curr Opin Pharmacol 2014; 19:61–6.
36. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514–9.
37. Bruno R, Sacchi P, Maiocchi L, et al. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis 2006; 38:363–73.
38. Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol 2013; 61:2397–405.
39. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015; 175:827–34.
40. Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis 2016; 36:109–16.